Frontiers in Immunology | Cancer Immunity and Immunotherapy

Original Research

Published on 23 Jul 2024

HIGD1B, as a novel prognostic biomarker, is involved in regulating the tumor microenvironment and immune cell infiltration; its overexpression leads to poor prognosis in gastric cancer patients

in Cancer Immunity and Immunotherapy

Shibo Wang
Siyi Zhang
Xiaoxuan Li
Xiangxue Li
Shufen Zhao
Jing Guo
Shasha Wang
Rui Wang
Mengqi Zhang
Wensheng Qiu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1415148

2,289 views
2 citations

Original Research

Published on 23 Jul 2024

Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma

in Cancer Immunity and Immunotherapy

Shengyong Zhai
Yuhua Li
Yuanyuan Yang
Wei Lang
Xiaoxia Liu
Kai Liu
Jianjun Qu
Lingyu Zhu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1361657

2,059 views
1 citation

Original Research

Published on 23 Jul 2024

Comprehensive investigation of tumor immune microenvironment and prognostic biomarkers in osteosarcoma through integrated bulk and single-cell transcriptomic analysis

in Cancer Immunity and Immunotherapy

Shaoyan Shi
Li Zhang
Xiaohua Guo

Frontiers in Immunology

doi 10.3389/fimmu.2024.1424950

2,385 views

Review

Published on 23 Jul 2024

LINC00518: a key player in tumor progression and clinical outcomes

in Cancer Immunity and Immunotherapy

Qiang Yi
Gangfeng Zhu
Weijian Zhu
Jiaqi Wang
Xinting Ouyang
Kuan Yang
Jinghua Zhong

Frontiers in Immunology

doi 10.3389/fimmu.2024.1419576

1,482 views

Original Research

Published on 23 Jul 2024

Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study

in Cancer Immunity and Immunotherapy

Wenyu Zhai
Chao Zhang
Fangfang Duan
Jingdun Xie
Shuqin Dai
Yaobin Lin
Qihang Yan
Bingyu Rao
Liang Li
Yuheng Zhou

Frontiers in Immunology

doi 10.3389/fimmu.2024.1422717

3,202 views
1 citation

Original Research

Published on 22 Jul 2024

Impact of mitochondrial damage on tumor microenvironment and immune response: a comprehensive bibliometric analysis

in Cancer Immunity and Immunotherapy

Yichun Xing
Yi Huang
Zhicheng Tang
Ying Lin
Yitong Zou
Yaqiang Huang
Zhaohui He
Qunxiong Huang
Jieying Wu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1442027

6,849 views

Original Research

Published on 22 Jul 2024

Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies

in Cancer Immunity and Immunotherapy

Lena Prantl
Philipp Heider
Lisa Bergmeister
Katharina Calana
Jan-Paul Bohn
Dominik Wolf
Zoltan Banki
Andreas Bosch
Maximilian Plach
Georg Huber

Frontiers in Immunology

doi 10.3389/fimmu.2024.1379023

1,616 views
2 citations

Original Research

Published on 22 Jul 2024

Advancing bladder cancer management: development of a prognostic model and personalized therapy

in Cancer Immunity and Immunotherapy

Xiang Huang
Guotu Du
Ying Yang
Peng Su
Shicheng Chen
Chongjiong Cai
Tianyu Huang
Yu Zeng
Yonggang Tao
Demei Tian

Frontiers in Immunology

doi 10.3389/fimmu.2024.1430792

2,351 views

Mini Review

Published on 22 Jul 2024

Targeting mitochondrial damage: shining a new light on immunotherapy

in Cancer Immunity and Immunotherapy

Wenjuan Zeng
Menghui Wang
Yuxin Zhang
Taicheng Zhou
Zhen Zong

Frontiers in Immunology

doi 10.3389/fimmu.2024.1432633

1,860 views

Review

Published on 19 Jul 2024

The role of innate immune cells in the colorectal cancer tumor microenvironment and advances in anti-tumor therapy research

in Cancer Immunity and Immunotherapy

Wenxuan Liu
Tianrui Kuang
Li Liu
Wenhong Deng

Frontiers in Immunology

doi 10.3389/fimmu.2024.1407449

4,198 views
2 citations

Original Research

Published on 19 Jul 2024

Circ_BBS9 as an early diagnostic biomarker for lung adenocarcinoma: direct interaction with IFIT3 in the modulation of tumor immune microenvironment

in Cancer Immunity and Immunotherapy

Daijun Peng
Mingyu Liang
Lingyu Li
Haisheng Yang
Di Fang
Lingling Chen
Bing Guan

Frontiers in Immunology

doi 10.3389/fimmu.2024.1344954

1,679 views
3 citations

Original Research

Published on 19 Jul 2024

The profile and prognostic significance of bone marrow T-cell differentiation subsets in adult AML at diagnosis

in Cancer Immunity and Immunotherapy

Kai Sun
Zong-Yan Shi
Ya-Zhe Wang
Dai-Hong Xie
Yan-Rong Liu
Qian Jiang
Hao Jiang
Xiao-Jun Huang
Ya-Zhen Qin

Frontiers in Immunology

doi 10.3389/fimmu.2024.1418792

1,836 views
2 citations

Review

Published on 19 Jul 2024

Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms

in Cancer Immunity and Immunotherapy

Biswanath Majumder
Nishanth Belugali Nataraj
Leela Maitreyi
Santanu Datta

Frontiers in Immunology

doi 10.3389/fimmu.2024.1414376

5,779 views
1 citation

Mini Review

Published on 19 Jul 2024

β-glucan: a potent adjuvant in immunotherapy for digestive tract tumors

in Cancer Immunity and Immunotherapy

Meiyu Wang
Jinhua Pan
Wu Xiang
Zilong You
Yue Zhang
Junyu Wang
Anren Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1424261

7,787 views
1 citation

Systematic Review

Published on 19 Jul 2024

Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis

in Cancer Immunity and Immunotherapy

Zhilong Huang
Chunyan Li
Yanping Huang
Weiming Liang
Haiyun Tao

Frontiers in Immunology

doi 10.3389/fimmu.2024.1425596

2,280 views
1 citation

Original Research

Published on 19 Jul 2024

iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma

in Cancer Immunity and Immunotherapy

Kate J. Dixon
Kristin M. Snyder
Melissa Khaw
Robert Hullsiek
Zachary B. Davis
Anders W. Matson
Soheila Shirinbak
Bryan Hancock
Ryan Bjordahl
Martin Hosking

Frontiers in Immunology

doi 10.3389/fimmu.2024.1407567

2,598 views

Navigation group

Articles

HIGD1B, as a novel prognostic biomarker, is involved in regulating the tumor microenvironment and immune cell infiltration; its overexpression leads to poor prognosis in gastric cancer patients

Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma

Comprehensive investigation of tumor immune microenvironment and prognostic biomarkers in osteosarcoma through integrated bulk and single-cell transcriptomic analysis

LINC00518: a key player in tumor progression and clinical outcomes

Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study

Impact of mitochondrial damage on tumor microenvironment and immune response: a comprehensive bibliometric analysis

Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies

Advancing bladder cancer management: development of a prognostic model and personalized therapy

Targeting mitochondrial damage: shining a new light on immunotherapy

The role of innate immune cells in the colorectal cancer tumor microenvironment and advances in anti-tumor therapy research

Circ_BBS9 as an early diagnostic biomarker for lung adenocarcinoma: direct interaction with IFIT3 in the modulation of tumor immune microenvironment

The profile and prognostic significance of bone marrow T-cell differentiation subsets in adult AML at diagnosis

Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms

β-glucan: a potent adjuvant in immunotherapy for digestive tract tumors

Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis

iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma